Fujian Shengdi Pharmaceutical
CompanyChina
Fujian Shengdi Pharmaceutical develops one asset, in phase 2 (HRS-7249 in hyperlipidemia). Mostly oligonucleotide acting on lipid and ceramide metabolism and APOC3; based in China.
- 1
- Asset
- Furthest stage
- Phase 2
- 9
- Trials
- 2
- Signals
Pipeline
1GalNAc-conjugated siRNA suppresses APOC3 expression to lower triglycerides.
Phase 2, Oligonucleotide, Lipid and ceramide metabolism, APOC3, hyperlipidemia
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials9
- Signals2
- Similar companies6